The 5th annual Bone and The Oncologist New Updates (bonus 5) conference, held at the National Arts Center, Ottawa, April 8-9, 2010, focused on innovative research into the mechanisms and consequences of increased bone turnover in the benign and metastatic settings alike. This year there was also a debate over the controversial use of bisphosphonates as an adjuvant treatment in patients with early-stage breast cancer. This meeting report highlights a few of the topics presented.
INTRODUCTION
Since their inception in 2005, the Bone and The Oncologist New Updates (bonus) meetings have covered a range of bone issues pertinent to health care professionals in oncology. The format of these single-day or day-and-a-half conferences has consisted of keynote lectures from national and international speakers. The topics covered have ranged from normal bone function to the effects of cancer and cancer therapies on normal and metastatic bone. A major part of the bonus meetings has also been to concentrate on the wealth of local research experience and exciting Canadian initiatives that will shape basic, translational, and clinical research in the future.
The 5th annual bonus conference (April 8-9, 2010) brought together clinicians, basic scientists, and others interested in the mechanisms and treatment of bone metastasis from breast cancer. Controversial topics about the adjuvant use of bisphosphonates to prevent breast cancer recurrences and the role of bone biomarkers and their clinical significance were discussed during the meeting. In an effort to encourage trainees to develop interest in bone research, five abstracts covering basic science and translational research were selected as oral poster presentations. Those abstracts can be found in the appendix to this article.
MEETING SESSIONS

Plenary Lecture: Intercellular Communication in Bone Metastasis
Presenter: Gurmit Singh, McMaster University and the Juravinski Cancer Centre, Hamilton, Ontario. Bone is the most frequent site of metastasis for breast and prostate cancers, often resulting in pathologic changes in bone metabolism and in severe pain. Our understanding of the biologic mechanisms involved is limited, although the most popular view is that the tumour cells initiate the release of factors from bone, which in turn stimulates tumour cells to proliferate and causes further bone degradation. The application of this hypothesis, often called the "vicious cycle" model, has led to the development of many therapeutic strategies aimed at disrupting the role that osteoclasts play in the process. Unfortunately, the "vicious cycle" does not fully account for many of the clinical features observed in patients. Although the model is predictive in osteolytic disease, it does not guide an understanding of the progression of the osteoblastic metastases common to many prostate cancers. Significantly, the model does not directly address the severe pain that is experienced by patients with either bone phenotype.
To complement the successes of the "vicious cycle," other models need to be developed to push forward in understanding this complex disease. An "intercellular communication hypothesis" has been developed that may be applied to this problem.
Many chemical factors released by tumour cells are known to interfere with the fine balance that exists in normal bone between bone resorption and formation. The amino acid and neurotransmitter glutamate has been shown to be a critical signalling molecule in bone homeostasis, and the cancer cell lines used to generate bone tumours in animals have been discovered to secrete significant amounts of glutamate in vitro. Furthermore, the molecular transport mechanism responsible for this glutamate release in vitro and in vivo has been identified, and its pharmacologic inhibition has been demonstrated. This aberrant chemical signal may be particularly disruptive in bone, because application of glutamate or modulation of its receptors and transporters significantly alters the differentiation and mature function of osteoclasts and osteoblasts alike. Because bone appears to be highly sensitive to glutamate disruption and is densely innervated with glutamate-sensitive neurons known to be involved in pain perception, it has been suggested that glutamate release by tumour cells is a plausible mechanism to account for many of the pathologic features of bone metastasis.
The suggestion that bone metastasis pathology may be the result of a "communication problem" represents a novel perspective in the understanding of cancer biology, and this concept may lead to practical targets for therapeutic intervention in bone metastasis and chronic bone cancer pain.
Plenary Lecture: Expression Profiling of Bone
Metastases from Patients with Breast Cancer
Presenter: Peter M. Siegel, McGill University, Montreal, Quebec. The most devastating aspect of breast cancer is the emergence of metastatic tumour cells that spread to distant organ sites. Indeed, 65%-75% of patients with advanced disease develop bone metastases. Numerous complications are associated with bone metastases, including pain, hypercalcemia, fracture, and spinal cord compressions, resulting in significant diminishment in the patient's quality of life. These complications can interfere with treatment, allowing tumour cells to spread to additional sites that are associated with a worse patient prognosis.
The use of bisphosphonates has demonstrated utility in reducing skeletal-related events, but there are notable limitations to the effectiveness of these agents as treatments. Thus, a better understanding of the molecular regulators controlling breast cancer metastasis to bone will provide additional targets that can be exploited in combination with existing therapies.
Typically, human or mouse breast cancer cell lines are used to further an understanding of the molecular mediators that direct metastasis to bone. These approaches have been informative, but they rely on established cell models and often fail to identify factors that are expressed in the metastatic lesion in situ. To circumvent these limitations, trephine biopsies have been obtained from breast cancer patients with radiographically confirmed bone metastases. In an analysis of 20 independent samples from either unguided or computed tomography-guided trephine biopsies, 5 bone metastases were identified that contained lesions of sufficient size for laser-capture microdissection (lcm). In each case, the presence of tumour cells was confirmed by immunofluorescence staining with antibodies specific for CK8/18 or CK5. Based on immunohistochemistry for estrogen receptor, progesterone receptor, and the human epidermal growth factor receptor 2, 4 of the bone metastases were derived from luminal breast cancers and the 5th was a triple-negative breast cancer. To facilitate the analyses, 5 primary breast tumours (4 luminal and 1 triple-negative) were also subjected to lcm, and rna from both sets of samples were amplified, labelled, and hybridized to Agilent Whole Human Genome microarrays (Agilent Technologies, Santa Clara, CA, U.S.A.).
Preliminary analysis of the resulting gene expression data has revealed that 117 genes were differentially expressed between the bone metastases and the primary tumours (filtered on a fold change > 3; p < 0.005). Among those genes, several candidates belonging to the human atp-binding cassette transporter family (drug resistance), Na+/K+ and Na+/ H+ pumps, and genes encoding proteins involved in actin cytoskeleton remodelling and motility were selectively upregulated within bone metastatic lesions. Thus, potential candidates associated with the bone metastatic phenotype can be identified using clinical samples of breast cancer bone metastases, coupled with lcm and gene-expression profiling.
Plenary Lecture: Normal Bone and Prevention of Cancer Therapy-Induced Bone Loss
Presenter: A.M.W. Cheung. University Health Network, Toronto, Ontario. Bone integrity is an important contributor to optimal quality of life in women with breast cancer. Dual-energy X-ray absorptiometry (dxa) bone densitometry is currently used as the imaging of choice for the diagnosis osteoporosis and cancer-induced bone loss. However, since the late 1990s, this technique-although inexpensive and easily accessible-has been found to have several limitations. For example, dxa bone densitometry does not predict which patients will have a skeletal event; instead, it gives information on the relative risk of experiencing an event. Another limitation is that dxa is a difficult tool to use to follow response to treatment.
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New imaging techniques that may provide researchers with more information about the microarchitecture of bone are currently being evaluated. One of those techniques is quantitative highresolution computed tomography (qhrct), which allows for better resolution of the cortical and trabecular bone microarchitecture. The importance of this new imaging modality is that it may correlate with skeletal events. Integrating a proper imaging modality into clinical trials can help in finding the answers to several long-standing questions, such as when to stop bisphosphonates in a patient with metastatic breast cancer, and whether bisphosphonates have an antitumour effect.
Do Bisphosphonates Have a Role in the Adjuvant
Treatment of Breast Cancer?
Presenters: Robert Coleman, University of Sheffield, Norton, U.K., and Allan Lipton, Pennsylvania State University, University Park, Pennsylvania, U.S.A.
Bisphosphonates offer a potentially effective adjuvant therapy to reduce recurrence of bone metastases in breast cancer patients. Clinical trials are at an early stage, but initial results have shown some promise. A number of adjuvant trials of oral clodronate, pamidronate, and zoledronic acid have been published or are on going [1] [2] [3] [4] [5] [6] [7] . Drs. Allan Lipton and Rob Coleman, both world leaders in this topic, debated the issue. Each speaker presented data both from preclinical studies and from subgroup analyses of studies including the three Zoledronic Acid-Letrozole Adjuvant Synergy Trials: z-fast (North America), zo-fast (Europe), and ezo-fast (rest of the world).
The largest placebo-controlled trial reported to date remains that of Powles et al. of oral clodronate 4 . This randomized placebo-controlled trial in 1069 women with primary operable breast cancer continues to show that, compared with placebo, clodronate resulted in a significantly lower incidence of bone metastasis: 45% lower during the first 2 years, and 31% lower during the 5-year study period. Overall survival time with clodronate was also a significantly longer than with placebo. After a 10.5-year followup, oral clodronate was still found to significantly improve overall survival.
Many studies are still ongoing, but two in particular will hopefully report soon. Accrual is complete for the National Surgical Adjuvant Breast and Bowel Project (nsabp) B34 trial, the fourth adjuvant clodronate trial. This double-blinded trial has randomized 3323 patients to either 1600 mg clodronate or placebo for 3 years. Also fully accrued is the 3360-patient azure (Adjuvant Zoledronic Acid to Reduce Recurrence) trial, which randomized patients with high risk or lymph-node-positive disease to either intravenous zoledronic acid or to control. The oncology community is waiting results from these and other studies.
Plenary Lecture: The Role of Biomarkers in Metastatic Disease and Prospects for Their Use in Early Breast Cancer
Presenter: Alexander Paterson, University of Calgary, Calgary, Alberta. Bone biomarkers have gained interest, especially with regard to their ability to measure the rate of bone resorption and formation. Although that information is insufficient to permit earlier diagnosis of bone metastases than is possible with imaging and clinical assessments, the rate of bone turnover, especially bone resorption, provides powerful and clinically useful prognostic and predictive information. Patients with high rates of turnover are more likely to experience a skeletal-related event. Decreases in the levels of bone biomarkers have been associated with successful treatment with agents such as bisphosphonates.
Further studies are needed to evaluate whether bone biomarkers can predict which patients would benefit from bisphosphonate therapy and how long therapy should be continued. This information would optimize bisphosphonate use and provide a more patient-oriented and cost-effective treatment. Bone biomarkers may find their place in oncology not only in selecting patients for bone-targeted treatment, in monitoring response, and in individualizing care, but also in the development of new treatment approaches.
Current Radiotherapy Research in Bone Metastases
Presenter: Alysa Fairchild, Cross Cancer Institute, Edmonton, Alberta.
Although approximately twenty-five randomized clinical trials (rcts) and three meta-analyses support the use of single-fraction radiotherapy (rt) in the treatment of uncomplicated bone metastases, practice differs significantly from published evidence. Some of the reasons postulated include toxicity, re-treatment issues, and geographic influences, all representing current controversies in rt. Dr. Fairchild presented a brief review of rt delivery methods and summarized the single-fraction studies, a National Cancer Institute of Canada-sponsored phase iii rct investigating repeat irradiation dosing, global patterns of practice, prevention of acute side effects ("pain flare"), and the emerging role of highly conformal rt.
Optimizing Bisphosphonate Therapy
Presenter: Eitan Amir, Princess Margaret Hospital and the University of Toronto, Toronto, Ontario.
Bisphosphonate therapy has become a standard of care for patients with malignant bone disease. In addition, preliminary clinical data suggest that bisphosphonates may prevent cancer-treatment-induced bone loss (ctibl) and the development of malignant bone disease in patients with early-stage cancer.
There is a lack of correlation between bone mineral density and fracture rates in ctibl, and new methods of predicting fracture risk are needed.
In the setting of metastatic bone disease, monitoring therapy remains difficult. Routine radiographs are sensitive, but not specific. Novel methods such as combined positron-emission tomography-computed tomography, possibly in combination with telopeptides should be further studied.
Finally, dose scheduling for bisphosphonates should be optimized. Many low-risk patients are probably over-treated with the current dose recommendations, and ongoing studies are investigating dose-reduced schedules.
Can We Afford the Cost of Progress in the Age of
New Targeted Therapies?
Presenter: George Dranitsaris, Consultant in Health and Biostatistics, Toronto, Ontario.
Globally, approximately 7.4 million people die annually from cancer, representing approximately 13% of deaths from all causes. As the population ages, we can expect a sharp increase in the number of new cancer cases over the next 10-20 years because cancer is more common in older people. Cancer is also associated with a substantial economic burden, both in terms of direct and indirect costs. In 19 European countries covered by the Organisation for European Cooperation and Development, the total annual expenditure for cancer care in 2004 was €54 billion (€120 per person). With respect to indirect costs, cancer was responsible for 16.7% of all disability adjusted life years (dalys) lost in 25 European countries and for 12.5% of all dalys lost in the United States and Canada. Despite the high impact of cancer on the number of dalys, only 4%-6% of annual health care budgets are allocated for the treatment of cancer. An argument can therefore be made that, despite the rising cost of cancer care, not enough is being spent, thus limiting the availability of new treatments. This presentation reviewed the international literature addressing the important challenges associated with patient access to new cancer drugs. In addition, strategies currently used by countries around the world to contain rising drug costs were presented.
SUMMARY
The bonus meetings continue to bring together people interested in bone disease and its implication in practice. The meetings continue to be an excellent forum to foster research and wide multidisciplinary interaction. We extend our thanks to all who made this meeting such a success, including our pharmaceutical sponsors. We will use the feedback from the bonus 5 conference to make further program changes before we start organizing the meeting for 2011! ‡ Division of Hematology and Oncology, The Princess Margaret Hospital, University of Toronto, Toronto, ON.
